Retatrutide 30mg

Within Europe this product is supplied including bacteriostatic water; outside Europe only the peptide vial is provided.

For research use only – not for human or veterinary use.

Product Overview
Retatrutide is a multi-agonist research peptide studied for its relevance to GLP GIP and glucagon-related signalling pathways. This lyophilized 30 mg preparation supports controlled laboratory evaluation of receptor-modulation behaviour, purity and identity under standardized research conditions.

Peptide Overview
Between 2018 and 2025 Retatrutide gained significant research attention for its tri-agonist activity and its modelling potential in metabolic-regulation studies. Its stable analytical profile enables reproducible in-vitro pathway assessment and multi-receptor interaction analysis.

Historical Background and Scientific Context
From 2020 onward, multi-pathway metabolic agonists became a central subject of biochemical research. Retatrutide emerged as a key reference peptide for modelling metabolic turnover, receptor synergy and complex pathway-regulation mechanisms in controlled environments.

Mechanistic Focus in Research

• Modelling of GLP GIP and glucagon receptor-pathway interactions
• In-vitro metabolic-synergy and signalling-pattern evaluation
• Comparative analysis with related tri-agonist peptides
• Biochemical modelling of energy-regulation pathways
• Controlled pathway-specific receptor-modelling experiments

Analytical Verification (COA)
Independent Liquilabs analysis confirms full analytical validation for Batch GF092025031. Key results include:

• Assay Content: 33.11 mg
• Identification – Retention Time: 1.00
• Identification – Spectrum: 100
• Purity: 99.6 percent
• Endotoxins: below 0.001 EU per mg
• Microbial Growth: not detected for aerobic count yeast or mold
• Heavy Metals: not detected including arsenic cadmium cobalt lead nickel mercury vanadium

All values were obtained using validated chromatographic spectroscopic and microbiological procedures ensuring transparency and traceability.

Research Applications

• Receptor-modulation and metabolic-signalling pathway modelling
• Multi-agonist biochemical interaction studies
• Comparative metabolic-regulation research
• Energy-balance pathway modelling
• Controlled in-vitro multi-pathway experimentation

Grail Formula Quality
Every Grail Formula research peptide undergoes independent laboratory verification for purity identity structural integrity and microbial safety. All batches are validated for reproducibility and stability to support consistent scientific outcomes.

When You Choose Grail Formula…
Researchers receive fully documented peptides with batch-number traceability sealed-vial integrity and transparent laboratory validation. EU shipments include sterile bacteriostatic water; outside the EU only the peptide vial is supplied.

For research use only – not for human or veterinary use.

• Verified and analysed with Liquilabs s.r.o. Czechia
• 99.6 percent purity with validated assay content
• No detectable heavy metals or microbial contamination
• Endotoxin below 0.001 EU per mg
• Batch GF092025031 – Published November 2025
• EU shipments include bacteriostatic water
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.